Pfizer's palbociclib wins 'breakthrough' status
This article was originally published in Scrip
Pfizer's experimental breast cancer agent palbociclib, an oral and selective inhibitor of cyclin dependent kinases 4 and 6, is the latest compound to gain the FDA's much sought-after breakthrough therapy designation – triggering a nearly 6% stock boost on 10 April for the company's partner Onyx Pharmaceuticals, which is entitled to 8% of the royalties on any worldwide sales of the product.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.